Galera Therapeutics, Inc. (GRTX)

NASDAQ: GRTX · IEX Real-Time Price · USD
0.250
+0.058 (30.26%)
At close: Feb 27, 2024, 4:00 PM
0.249
-0.001 (-0.44%)
After-hours: Feb 27, 2024, 7:59 PM EST
30.26%
Market Cap 10.44M
Revenue (ttm) n/a
Net Income (ttm) -69.68M
Shares Out 54.39M
EPS (ttm) -1.89
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 25,881,612
Open 0.215
Previous Close 0.192
Day's Range 0.203 - 0.260
52-Week Range 0.085 - 3.590
Beta 2.17
Analysts Hold
Price Target 0.35 (+39.94%)
Earnings Date Mar 11, 2024

About GRTX

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 7, 2019
Employees 31
Stock Exchange NASDAQ
Ticker Symbol GRTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for GRTX stock is "Hold." The 12-month stock price forecast is $0.35, which is an increase of 39.94% from the latest price.

Price Target
$0.35
(39.94% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates

FDA confirms need for new trial for avasopasem; GRECO trials with rucosopasem to be discontinued Company evaluating potential strategic options to optimize shareholder value MALVERN, Pa., Nov. 14, 202...

3 months ago - GlobeNewsWire

Galera Announces Receipt of Type A Meeting Minutes and Strategic Update

FDA confirms need for new trial for avasopasem for severe oral mucositis (SOM) GRECO-2 trial did not pass futility analysis; Company will discontinue both GRECO trials Company reviewing potential stra...

4 months ago - GlobeNewsWire

Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem

MALVERN, Pa., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, pro...

5 months ago - GlobeNewsWire

Top 5 Health Care Stocks That May Explode In Q3 - BioVie (NASDAQ:BIVI), Galera Therapeutics (NASDAQ:GRTX)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: BIVIISPCMEOMIC
6 months ago - Benzinga

Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates

Company received Complete Response Letter from FDA for avasopasem and intends to request Type A meeting with FDA to discuss potential next steps

7 months ago - GlobeNewsWire

Galera shares tank after US FDA declines to approve inflammation disease drug

Galera Therapeutics Inc said the U.S. health regulator declined to approve its drug to treat radiotherapy-induced severe mouth inflammation in patients with advanced head and neck cancer undergoing st...

7 months ago - Reuters

Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese

The Company remains committed to its goal of bringing avasopasem to patients and intends to meet with FDA as soon as possible to discuss potential next steps

7 months ago - GlobeNewsWire

Galera Presents Additional Chronic Kidney Disease Data from ROMAN Trial at 2023 ASCO Annual Meeting

As previously reported, avasopasem reduced cisplatin-related chronic kidney disease by 50% compared to placebo at one-year follow-up

9 months ago - GlobeNewsWire

Galera Reports First Quarter 2023 Financial Results and Recent Corporate Updates

Avasopasem NDA granted FDA priority review for radiotherapy-induced severe oral mucositis (SOM); PDUFA target date of August 9, 2023

10 months ago - GlobeNewsWire

Galera Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., May 04, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, propr...

10 months ago - GlobeNewsWire

Galera Expands Commercial Leadership Team

Company appoints leading sales, market access and operations executives with decades of experience successfully launching and commercializing new oncology products

10 months ago - GlobeNewsWire

Galera to Present One-Year Reductions in Cisplatin-Related Chronic Kidney Disease Data from ROMAN Trial at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

MALVERN, Pa., April 26, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, pro...

10 months ago - GlobeNewsWire

Galera Announces Presentation of Supplemental Analysis of Phase 3 ROMAN Trial at European Congress on Head and Neck Oncology

MALVERN, Pa., March 10, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, pro...

1 year ago - GlobeNewsWire

Galera Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates

Avasopasem NDA granted FDA priority review for radiotherapy-induced severe oral mucositis (SOM); PDUFA target date of August 9, 2023

1 year ago - GlobeNewsWire

Galera Therapeutics Announces Pricing of Registered Direct Offering of $30 Million of Common Stock and Warrants

MALVERN, Pa., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, prop...

1 year ago - GlobeNewsWire

Galera Submits New Drug Application for Avasopasem for Severe Oral Mucositis

NDA based on two positive randomized, double-blinded, placebo-controlled trials which enrolled a total of 678 patients NDA based on two positive randomized, double-blinded, placebo-controlled trials w...

1 year ago - GlobeNewsWire

Galera to Present at Piper Sandler Annual Healthcare Conference

MALVERN, Pa., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, prop...

1 year ago - GlobeNewsWire

Galera Reports Third Quarter 2022 Financial Results and Recent Corporate Updates

Company on track to submit NDA to U.S. FDA for avasopasem by end of 2022

1 year ago - GlobeNewsWire

Galera Announces Presentation of Phase 3 ROMAN Long-term Follow-up Data at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting

Tumor outcomes and overall survival maintained in patients with HNC at one-year

1 year ago - GlobeNewsWire

Galera to Present at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting

MALVERN, Pa., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, pro...

1 year ago - GlobeNewsWire

Galera to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

MALVERN, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, pro...

1 year ago - GlobeNewsWire

Galera Appoints Eugene P. Kennedy, M.D.

MALVERN, Pa., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, pro...

1 year ago - GlobeNewsWire

Galera Reports Second Quarter 2022 Financial Results and Recent Corporate Updates

Company on track to submit NDA to U.S. FDA for avasopasem by end of 2022

1 year ago - GlobeNewsWire

Galera Therapeutics' Rucosopasem Shows Early Anti-Cancer Activity, Pulmonary Function Preservation

Galera Therapeutics Inc (NASDAQ: GRTX) announced results from the open-label Phase 1 stage of the GRECO-1 trial of rucosopasem in combination with stereotactic body radiation therapy (SBRT) for non-sm...

1 year ago - Benzinga

Galera Announces Results from Phase 1 Stage of GRECO-1 Trial of Rucosopasem with SBRT for NSCLC

Rucosopasem was safe and well tolerated

1 year ago - GlobeNewsWire